Therapies for treating inflammatory disorders
AssigneeMicroPharm Limited
InventorsJohn Landon, Ruth Elizabeth Coxon
Life of this patent
Estimating the term…
Abstract
The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.
Claims36
An antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα), and means for protecting the antibodies during gastrointestinal transit.
The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises at least a protease inhibitor.
The antibody composition according to any one of the preceding claims formulated as a liquid.
The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises a means obtainable from egg white.
The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises egg white, preferably powdered egg white.
The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises one or more antacid(s).
The antibody composition according to any one of the preceding claims, wherein the means for protecting the antibodies comprises one or more of:
- a. a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/or chymotrypsin;
- and/or
- b. an antibody that binds to trypsin and/or chymotrypsin and suppresses or inactivates the protease activity of said trypsin and/or chymotrypsin;
- and/or
- c. an antacid.
The antibody composition according to any one of the preceding claims, wherein the composition comprises an antacid and:
- a. a polypeptide which binds specifically to and suppresses or inactivates the proteolytic activity of trypsin and/or chymotrypsin;
- and/or
- b. an antibody that binds to trypsin and/or chymotrypsin and inactivates the protease activity of said trypsin and/or chymotrypsin.
The antibody composition according to any one of the preceding claims, wherein the means comprises one or more of ovomucoid, ovostatin, ovomacroglobulin, or combinations thereof.
The antibody composition according to any one of the preceding claims, wherein at least 5% of the total antibodies present in the composition bind to TNFα.
The antibody composition according to any one of the preceding claims, wherein at least 10% of the total antibodies present in the composition bind to TNFα.
A method for manufacturing intact blood-derived polyclonal antibodies that bind to human tumour necrosis factor α (TNFα), said method comprising obtaining a blood sample from a non-human mammal that has been administered an immunogen comprising human TNFα or a fragment thereof.
Dependencies are inferred from the claim text.